RxDoctor Payments DataLook up a doctor →

Steve Fordan, MD

Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1245432582

Payments from drug & device makers

$2,816,267in general payments, 2019–2025

Across 4,876 payments — averaging $577.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$916K
  • Lilly USA, LLC$633K
  • Eli Lilly$444K
  • Novo Nordisk$280K
  • Bayer$105K
  • Boehringer Ingelheim$102K
  • plus $335K from 54 others
$6,151in research payments, 2019–2025

Across 5 payments — averaging $1230.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$6K
  • Novo Nordisk AS$100

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS1,674$916,345
Lilly USA, LLC1,203$633,024
Eli Lilly12$444,146
Novo Nordisk403$279,794
Bayer177$105,452
Boehringer Ingelheim220$102,310
Kowa Research Institute, Inc.33$78,343
Amgen(2 entities)131$61,150
Sanofi US Services Inc.13$49,736
Sanofi-aventis U.S. LLC89$38,007
Merck73$34,508
Takeda Pharmaceuticals U.S.A., Inc.30$21,800
AstraZeneca(2 entities)68$12,551
Xeris Pharmaceuticals, Inc.96$8,903
Mannkind Corporation94$8,460
Johnson & Johnson12$4,390
Zealand Pharma US, Inc.21$2,942
Abbott65$2,642
Gilead6$1,811
AbbVie38$1,544
Medtronic(2 entities)40$1,054
Corcept Therapeutics50$974
Dexcom, Inc.46$729
Amarin Pharma, Inc.34$658
Radius Health, Inc.27$507
Sequel Med Tech, LLC16$478
Insulet Corporation27$439
Madrigal Pharmaceuticals19$357
Amneal Pharmaceuticals LLC19$349
Astellas Pharma US Inc12$278
Ascendis Pharma Endocrinology Inc9$215
IBSA Pharma Inc.12$195
Tandem Diabetes Care, Inc.9$191
Cequr Corporation4$177
Novartis7$154
Verity Pharmaceuticals Inc.6$151
Valeritas, Inc.7$131
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$113
Esperion Therapeutics, Inc.6$108
Arbor Pharmaceuticals, Inc.6$103
Antares Pharma, Inc.6$95
BETA Bionics, Inc.7$93
Kowa Pharmaceuticals America, Inc.5$77
Alvogen Inc3$68
Azurity Pharmaceuticals, Inc.3$65
Lexicon Pharmaceuticals, Inc.1$58
Tolmar, Inc.3$53
Echosens North America, Inc.2$53
Intuity Medical Inc3$51
Janssen Scientific Affairs, LLC1$49
Lifescan, Inc.3$46
Nevro Corp.2$34
BD2$30
Halozyme Inc2$30
Soleno Therapeutics, Inc.1$30
Neurocrine Biosciences, Inc.1$29
Ultragenyx Pharmaceutical Inc.1$25
Vivus LLC2$25
Sun Pharmaceutical Industries Inc.1$20
Shire North American Group Inc1$19

How this compares

$2,816,267 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$128,438
Medicare patients
299
Services billed
1,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →